340bemployed.org

Your Free Source for 340B News and Commentary

  • Home
  • About Us
  • Employers
  • Job Seekers
  • Advertise
  • 340B Health

Senator Slams CMS Response to Questions About EpiPen


 

Print Article

January 26, 2017—Sen. Chuck Grassley (R-Iowa) is ramping up pressure on the Centers for Medicare and Medicaid Services to hand over documents about Mylan Pharmaceuticals’ misclassification of EpiPen as a generic drug and subsequent underpayment of Medicaid rebates. [ms-protect-content id=”2799″]

“We need records,” the senator wrote to CMS Acting Administrator Patrick Conway on Jan. 19. “Provide us with records.  If this is not plain, just talk with my staff and they will be very specific.”

Senator Grassley complained in the letter to Conway about former Acting Administrator’s Andrew Slavitt’s “lackluster and very disappointing” Jan. 18 response to the senator’s previous requests for information about CMS’s communications with Mylan and whether CMS took steps to hold Mylan accountable. Slavitt told Senator Grassley that while CMS believes Mylan misclassified EpiPen and underpaid rebates, CMS lacks statutory authority to compel a manufacturer to reclassify a drug or to issue civil monetary penalties in such a case.

“CMS seems to suggest it lacks the authority to compel drug companies to classify their drugs properly,” Senator Grassley wrote to Conway. “If that’s the case, why didn’t Congress hear this before now? Is the intent to do little or nothing and then when confronted, blame the inaction on a supposed lack of authority? Didn’t CMS have the authority and the obligation to report clear violations of the law to the Justice Department and if so, has it done so in the case of EpiPens and other misclassified drugs?”

“CMS is trying to dodge responsibility for a problem that likely cost the taxpayers hundreds of millions of dollars and damaged Medicaid program integrity,” Senator Grassley wrote. “This won’t stand.”

In December, Senate Finance Committee Chairman Orrin Hatch (R-Utah), then House Energy & Commerce Committee Chairman Fred Upton (R-Mich.), then E&C Health Subcommittee Chair Joseph Pitts (R-Pa.), and E&C Oversight Subcommittee Chair Tim Murphy (R-Pa.) wrote separately to Slavitt about CMS’s handling of the EpiPen matter. Among other questions, they asked whether EpiPen’s misclassification as a generic drug for Medicaid rebate purposes caused hospitals and other healthcare providers in the 340B drug discount program to be overcharged. Slavitt’s response has not come to light.

Hospitals and health systems in the 340B program have asked the U.S. Justice Department to investigate whether Mylan overcharged 340B healthcare providers for EpiPens.


Register – 340B Coalition Winter Conference – February 1-3, 2017 – San Francisco, Calif. [/ms-protect-content]

Follow us on X

340B Health Follow

340B Health is the leading advocate & resource for hospitals that serve their communities by participating in the 340B drug pricing program. #Protect340B

340BHealth
340bhealth 340B Health @340bhealth ·
14 Jul

#Becauseof340B savings, Johnson County Hospital in rural Nebraska can provide health care services that otherwise would operate at a loss. By helping fund toenail care clinics, ambulance services, and more, #340B empowers patients to access care, regardless of their ability to…

Reply on Twitter 1944780343556583424 Retweet on Twitter 1944780343556583424 Like on Twitter 1944780343556583424 Twitter 1944780343556583424
340bhealth 340B Health @340bhealth ·
12 Jul

WAC, GPO, and #340B, oh my!
Our latest #340BInsight explains some of these terms and other key concepts 340B hospitals need to know when creating a drug purchasing strategy. Don’t miss it: http://bit.ly/3YWHlJ4.

Reply on Twitter 1944100948160430424 Retweet on Twitter 1944100948160430424 Like on Twitter 1944100948160430424 Twitter 1944100948160430424
340bhealth 340B Health @340bhealth ·
11 Jul

.@drgnayyar is a chief medical officer, technologist, and one of the keynote speakers for the upcoming @340BCoalition #340BConf! In just a few weeks, Dr. Nayyar will address attendees on the dangers of health misinformation and ways providers can help combat this problem.

Reply on Twitter 1943769514396823563 Retweet on Twitter 1943769514396823563 Like on Twitter 1943769514396823563 1 Twitter 1943769514396823563
Load More

RSS 340B Informed

  • An In-Depth Look at Total 340B Purchases
  • Ideas for 340B Changes Could Lead to Legislation
  • Help From 340B After a Rare Diagnosis and an Unaffordable Bill

Copyright © 2025 · 340B Health